

CLAIM AMENDMENTS

1-10. (canceled)

11. (previously presented) A method of treating inflammatory or obstructive airways disease while avoiding, ameliorating or restricting side effects associated with the administration of racemic terbutaline, the method comprising administering to a human subject in need of such treatment, a therapeutically effective amount of terbutaline, the amount comprising greater than 98% *R*-terbutaline.
12. (previously presented) The method according to claim 1, wherein the side effects avoided, ameliorated or restricted are deleterious to the airways.
13. (previously presented) The method according to claim 1, wherein the side effect is exacerbation of basal disease status or compromise or deterioration of lung function.
14. (canceled) ~~The method according to claim 1, further comprising the administration of an anti-asthmatic amount of ketotifen.~~
15. (previously presented) An inhalable terbutaline composition comprising greater than 98% *R*-terbutaline and a pharmaceutically acceptable carrier.